LeMaitre Vascular (NASDAQ:LMAT) Insider Sells $115,142.76 in Stock

LeMaitre Vascular, Inc. (NASDAQ:LMAT) insider Trent Kamke sold 1,044 shares of LeMaitre Vascular stock in a transaction on Friday, February 27th. The stock was sold at an average price of $110.29, for a total transaction of $115,142.76. Following the completion of the sale, the insider owned 6,677 shares of the company’s stock, valued at approximately $736,406.33. This trade represents a 13.52% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

LeMaitre Vascular Stock Down 0.7%

NASDAQ LMAT traded down $0.79 during trading hours on Monday, reaching $107.39. 330,860 shares of the company traded hands, compared to its average volume of 213,077. LeMaitre Vascular, Inc. has a 12 month low of $71.42 and a 12 month high of $115.33. The company has a current ratio of 12.89, a quick ratio of 10.95 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $2.45 billion, a PE ratio of 42.78, a PEG ratio of 2.01 and a beta of 0.66. The company has a 50 day moving average of $87.47 and a two-hundred day moving average of $88.40.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Wednesday, February 25th. The medical instruments supplier reported $0.68 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.01. LeMaitre Vascular had a net margin of 23.13% and a return on equity of 14.72%. The company had revenue of $64.45 million during the quarter, compared to the consensus estimate of $62.98 million. During the same quarter in the previous year, the firm earned $0.49 EPS. The company’s revenue was up 15.7% on a year-over-year basis. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. As a group, equities analysts expect that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 26th. Stockholders of record on Thursday, March 12th will be issued a $0.25 dividend. This is a positive change from LeMaitre Vascular’s previous quarterly dividend of $0.20. The ex-dividend date is Thursday, March 12th. This represents a $1.00 dividend on an annualized basis and a dividend yield of 0.9%. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 31.87%.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the stock. Wall Street Zen upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Weiss Ratings downgraded shares of LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, February 24th. Cantor Fitzgerald reissued a “neutral” rating and issued a $95.00 target price on shares of LeMaitre Vascular in a report on Monday, November 10th. Zacks Research downgraded LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 1st. Finally, Wells Fargo & Company upped their target price on LeMaitre Vascular from $87.00 to $94.00 and gave the company an “equal weight” rating in a report on Thursday. Three analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $105.80.

Institutional Trading of LeMaitre Vascular

Several large investors have recently added to or reduced their stakes in LMAT. Mercer Global Advisors Inc. ADV boosted its stake in shares of LeMaitre Vascular by 11.5% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 3,606 shares of the medical instruments supplier’s stock worth $292,000 after acquiring an additional 371 shares in the last quarter. NewEdge Advisors LLC lifted its holdings in shares of LeMaitre Vascular by 4.6% during the fourth quarter. NewEdge Advisors LLC now owns 3,158 shares of the medical instruments supplier’s stock valued at $256,000 after purchasing an additional 139 shares during the last quarter. Empowered Funds LLC acquired a new position in shares of LeMaitre Vascular in the 4th quarter valued at $289,000. nVerses Capital LLC acquired a new position in shares of LeMaitre Vascular in the 4th quarter valued at $234,000. Finally, Voloridge Investment Management LLC increased its stake in LeMaitre Vascular by 70.0% in the 4th quarter. Voloridge Investment Management LLC now owns 62,909 shares of the medical instruments supplier’s stock worth $5,102,000 after purchasing an additional 25,901 shares in the last quarter. 84.64% of the stock is currently owned by institutional investors and hedge funds.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.